Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Go back to Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy| (NASDAQ: NRIX) | Delayed: 26.14 +0.82 (3.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.32 | 52 Week High | $ | |||
| Open | $25.19 | 52 Week Low | $ | |||
| Day High | $26.22 | P/E | N/A | |||
| Day Low | $24.97 | EPS | $ | |||
| Volume | 1,232,152 | |||||
